FDA accepts Lundbeck application
The FDA has agreed to review a registration application for one of Lundbeck’s major drug hopes.
BY BENJAMIN WERNER CHRISTENSEN
The US Food and Drug Administration, FDA, has accepted a registration application from Danish pharma group Lundbeck and its Japan-based partner Otsuka, asking for marketing authorization for one of their major pipeline hopes, schizophrenia and depression treatment brexpiprazol, Lundbeck writes in a press release.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Diamond in the rough in Lundbeck’s pipeline
For abonnenter
Analyst: Lundbeck could reach 2020 targets, but…
For abonnenter
